Geode Capital Management LLC Buys 14,199 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX)

Geode Capital Management LLC raised its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 9.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 163,242 shares of the company’s stock after purchasing an additional 14,199 shares during the period. Geode Capital Management LLC owned 0.97% of Unity Biotechnology worth $240,000 as of its most recent SEC filing.

Separately, Ballentine Partners LLC purchased a new position in shares of Unity Biotechnology in the third quarter valued at about $84,000. Institutional investors and hedge funds own 29.49% of the company’s stock.

Analyst Ratings Changes

Separately, Chardan Capital started coverage on Unity Biotechnology in a research report on Friday. They issued a “buy” rating and a $6.00 price objective on the stock.

Unity Biotechnology Stock Performance

UBX opened at $1.72 on Tuesday. The stock has a market cap of $28.98 million, a price-to-earnings ratio of -1.31 and a beta of 0.80. The stock’s 50 day moving average price is $1.18 and its 200-day moving average price is $1.36. Unity Biotechnology, Inc. has a one year low of $0.94 and a one year high of $2.02.

Unity Biotechnology (NASDAQ:UBX) last released its earnings results on Monday, November 4th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. As a group, analysts predict that Unity Biotechnology, Inc. will post -1.49 earnings per share for the current fiscal year.

Unity Biotechnology Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.